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Riccardo RicciAbstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of gastrointestinal tract.
They feature heterogeneous triggering mechanisms, implying relevant clinical differences. The vast majority of GISTs
are sporadic tumors. Rarely, however, GIST-prone syndromes occur, mostly depending on heritable GIST
predisposing molecular defects involving the entire organism. These conditions need to be properly identified in
order to plan appropriate diagnostic, prognostic and therapeutic procedures.
Clinically, GIST-prone syndromes must be thought of whenever GISTs are multiple and/or associated with
accompanying signs peculiar to the background tumorigenic trigger, either in single individuals or in kindreds.
Moreover, syndromic GISTs, individually considered, tend to show distinctive features depending on the underlying
condition. When applicable, genotyping is usually confirmatory.
In GIST-prone conditions, the prognostic features of each GIST, defined according to the criteria routinely applied to
sporadic GISTs, combine with the characters proper to the background syndromes, defining peculiar clinical settings
which challenge physicians to undertake complex decisions. The latter concern preventive therapy and single
tumor therapy, implying possible surgical and molecularly targeted options.
In the absence of specific comprehensive guidelines, this review will highlight the traits characteristic of GIST-
predisposing syndromes, with particular emphasis on diagnostic, prognostic and therapeutic implications, which
can help the clinical management of these rare diseases.
Keywords: Syndromic GIST, Hereditary GIST, Familial GIST, PDGFRA-mutant syndrome, Carney’s triad, Carney-
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Gastrointestinal (GI) stromal tumors (GISTs) are the
most common GI mesenchymal neoplasms [1, 2]. They
generally express KIT (CD117) and DOG1, similar to
interstitial cells of Cajal (ICC) [3, 4].
GISTs have been a paradigm of molecular targeted ther-
apy since they revealed activating KIT mutations [5], lead-
ing to the successful employment of the tyrosin kinase
(TK) inhibitor (TKI) imatinib [6]. Since then, besides KIT
mutations (~¾ of cases), GISTs have revealed other possible
triggers: platelet-derived growth factor (PDGF) receptor α
(PDGFRA) mutations (~7 %), succinate dehydrogenase
(SDH) complex deficiency (~5 %, half of which depending
on mutations of SDH subunits), and mutations of BRAF
(2 %) or neurofibromatosis type 1 (NF1) (1, 5 %). This het-
erogeneity implies different pathogenic, diagnostic andCorrespondence: riccardo.ricci@unicatt.it
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entailing diverse therapeutic approaches [1].
All of these pathogenic mechanisms but BRAF muta-
tions have been rarely described to involve the entire or-
ganism, causing syndromes featuring multiple GISTs
and peculiar associated signs. The resulting repertoire of
syndromic GISTs constitute ~3-4 % of GISTs. Within
them, NF1-associated GISTs prevail [1]. Much rarer are
GISTs hinging upon germline KIT or PDGFRA muta-
tions, with <50 kindreds/individuals described [7–48].
An overall favorable prognosis has been attributed to
GISTs when multiple (including syndromic ones), no
matter their number/phenotype [27]. However, despite
the relatively high fraction of indolent GISTs due to NF1
or SDH-deficiency, “multiple GISTs” is a crucible where
heterogeneous conditions merge in, differing in patho-
genesis, prognosis and therapy. The approach to syn-
dromic GISTs must therefore be personalized,
considering the characters of both individual tumors,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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ground syndrome, defining peculiar clinical settings.
GIST-predisposing syndromes will be herein reviewed,
emphasizing inherent diagnostic, prognostic and thera-
peutic implications. Additionally, pertinent fundamentals
of GIST pathogenesis will be recalled.
Features of GIST-predisposing syndromes
KIT mutant syndrome
KIT is a transmembrane type III TK receptor (TKR),
whose gene is mapped to 4q12. Physiologically, KIT
activation follows homodimerization upon stem cell
factor (SCF) binding. Mutated KIT homodimerizes in
a ligand-independent way. Activated KIT initiates
RAS/MAPK, PI3K/AKT/mTOR and JAK/STAT3 sig-
naling [49–51] (Fig. 1).
At the best of my knowledge, germline KIT-mutant
GISTs have been described in 31 kindreds and 6 individ-
uals without familial history [7–44]. Additionally, unge-
notyped kindreds with signs coherent with KIT-
dependent familial GISTs have been described prior to
the discovery of KIT role in GISTs [52–55].
Average age-at-diagnosis of germline KIT-dependent
GISTs anticipates that of sporadic cases of ~10 years:
late forties/early fifties versus early/middle sixties [20,
29, 56–58]. This is true also if, in case of KIT-mutantFig. 1 Molecular triggers and intracellular pathways involved in syndromic GI
one of the following (evidenced with a halo): KIT, PDGFRA, neurofibromin or
involving multiple pathways: RAS/RAF/MEK/ERK (MAPK) (left, green hue); JAK/
hue), stimulating oncogenic gene transcription or protein synthesis. In NF1-as
RAS inhibiting effect, resulting in the activation of MAPK cascade downstream
succinate conversion to fumarate. Accumulated succinate inhibits prolyl-hydro
this molecule which, consequently, heterodimerizes with HIF1-β and transloc
Furthermore, succinate accumulation inhibits TET DNA hydroxylases resulting
required for DNA demethylation, thereby influencing gene expressionkindreds, only the first individuals diagnosed with GIST
(or GIST-compatible tumors in “pre-KIT era”) are con-
sidered, resulting in a 48-year mean, not influenced by
familial screening. This anticipation likely parallels the
early GIST trigger intrinsic to the connatal KIT muta-
tion. The probability of GIST diagnosis in germline KIT-
mutants increases with age, raising from 0.077 before
the age of 40 to 0.462 by the age of 50 [29]. The age-at-
diagnosis decrease reported in successive generations
[17] is possibly due to subclinical GISTs diagnosed at
screening.
KIT-mutant syndrome features no sex predilection, as
expected given its autosomal dominant inheritance.
Penetrance for GISTs is high [13, 20], unlike that for al-
tered skin pigmentation [29].
Familial KIT-mutant GISTs occur along the whole GI
tract (especially in small bowel/stomach), featuring a
spindle, epithelioid or spindle-and-epithelioid citology
(with the former prevailing), commonly expressing
CD117 and DOG1 (Table 1), similar to their sporadic
counterparts.
As shown in Table 1, other features of germline KIT
mutants include: diffuse ICC hyperplasia (ICCH) (with
related peristalsis disturbances), skin pigmentation alter-
ations and mast-cell disorders. Sporadically, melanoma,
non-GIST stromal tumors and breast cancer have beenST arousal. Syndromic GISTs reported so far hinge upon alterations of
SDH. KIT and PDGFRA activation initiates a downstream signaling
STAT3 (centre, blue hue); and PI3K/AKT/mTOR (top right, yellow/brown
sociated GISTs, tumoral inactivation of the WT neurofibromin impairs its
to KIT and PDGFRA. Impairment of the SDH enzymatic complex prevents
xylase; the missed hydroxylation of HIF1-α prevents the degradation of
ates into the nucleus acting as an oncogenic transcription factor.
in impaired conversion of 5-methylcytosine to 5-hydroxymethylcytosine,














Nishida et al. [7] family 11 (p.V560del) SIe S, Mf Perineal hyperpigmentation
O’Brien et al. [8]; Hirota et al.
[9]; Chen et al. [10]
family 11 (p.W557R) SI S, M yes yes
Isozaki et al. [11]; Handra-Luca
et al. [12]; Bachet et al. [13]
family 13 (p.K642E) ST, SI S, M yes yes Lentigines on trunk, limbs,
palms and soles
Dysphagia
Maeyama et al. [14] family 11 (p.V559A) ST, SI S Hyperpigmentation and nevi





Hirota et al. [16] family 17 (p.D820Y) ST, SI Mf yes Dysphagia




Antonescu et al. [18] individual 11 (p.W557R) ST, SI S yes
Carballo et al. [19] family 11
(p.L756_P577InsQL)
ST, SI S yes Hyperpigmentation of
neck, hands, feet and
circumoral area
Li et al. [20] family 11 (p.V559A) ST, SI Sg yes Hyperpigmentation,
lentigines, café-au-lait
maculesh, nevi (all these
lesions variably involved
neck, perioral area, scrotal
region/pelvic/genital/inguinal






Tarn et al. [21] family 11 (p.D579del) ST M yes
Hartmann et al. [22] family 8 (p.D419del) SI M yes Mastocytosis Dysphagia
Kim et al. [23] individual 11 (p.V559A) SI S, M yes
O’Riain et al. [24] family 17 (p.D820Y) ST,
SI,
ICV
Mf, S yes yes Dysphagia Small bowel
Miettinen et al. [25]; Lasota
and Miettinen [26]
family 11 (p.D579del) SI, A,
C
NS
Kang et al. [27] family 11 (p.V560G) SI NS yes Hyperpigmentation
Kang et al. [27] individual 11 (p.V559A) SI NS yes











Table 1 Kindreds and individuals affected by gastrointestinal stromal tumors associated with germline KIT mutations (Continued)
E, ST,
SI, R
Kleinbaum et al. [29] family 11 (c.D579del) ST,
SI, C
S yes yes Hyperpigmentation, nevi
Woźniak et al. [30] family 11
(p.Q575_577delinsH)
R S, M yes Constipation




Campbell et al. [32] family 11 (NSi) ST,
SI, C
NS Dysplastic nevi, lentigines,
darkening of labia
minora pudendi
Veiga et al. [33] family 17 (p.D820Y) ST,
SI, R
NS yes 1 endometrial stromal
sarcoma
Kuroda et al. [34] family 11 (p. V559A) ST,
SI, C
S yes Hyperpigmentation of
external genitalia and axilla
Vilain et al. [35] family 13 (p. K642E) ST, SI Sf yes Hyperpigmentation
(multiple nevi in the axillae




with WSj type 2
Dysphagia Oesophagus
Nakai et al. [36] family 11 (p. Y553K) ST,
SI, C
NS yes
Wadt et al. [37] family 13 (p.K642E) ST, SI NS yes yes 1 breast cancer
Speight et al. [38] individual 9 (p.K509I) SI S Mastocytosis
Bachet et al. [13] family 13 (p.K642E) ST,
SI, C,
R
S yes yes Lentigines and nevi Multiple cutaneous
angiolypomas in one
individual
Bachet et al. [13] family 13 (p.K642E) ST, SI S yes
Neuhann et al. [39] family 11 (p.L576P) ST,
SI, C
S yes Multiple lentigines on face,
neck, chest, back, axillae, legs
Achalasia,
dysphagia











Table 1 Kindreds and individuals affected by gastrointestinal stromal tumors associated with germline KIT mutations (Continued)




Jones et al. [42] family 11 (p.D579del) ST, SI S
Jones et al. [42] family 11 (p.D579del) ST, SI S
Bamba et al. [43] family 11 (p.V560del) ST, SI S
Forde et al. [44] family 11 (p.D579del) ST, SI NS Skin hyperpigmentation Dysphagia
a E esophagus, ST stomach, SI small intestine, ICV ileocecal valve, A appendix, C colon, R rectum, NS not specified
b S spindle cell, E epithelioid, M mixed spindle cell and epithelioid, NS not specified
c M, GIST metastases
d Diffuse Intersitial cell of Cajal hyperplasia
e inferred from the mention of intestinal obstruction
f inferred from published microphotographs
g not specified in the referred paper; inferred from the diagnosis of “neurofibromatosis” previously made in several of the family members
h café-au-lait macules were reported in one of the individuals originally thought to have neurofibromatosis; this could have influenced the term used
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of the former [49]; the latter two are likely incidental.
Sometimes, non-GIST signs are the first reason for pa-
tients to seek medical help [15, 32, 35, 41, 44].
Skin pigmentation defects mostly occur in excess;
nevertheless, hypopigmentation has been reported [28,
35]. Of note, lentigines and vitiligo can coexist [20]. Fi-
nally, pigmentation alterations consistent with Waarden-
burg syndrome type 2 have also been reported in the
absence of pathognomonic mutations, candidating the
detected KIT variant among the possible causes of this
disease [35].
The role of KIT in ICC development and gut motility
regulation, and in the development and neoplastic trans-
formation of melanocytes and mast cells [49], explains
some of the germline KIT-mutants’ features. Conversely,
the variable manifestations of these signs have not been
satisfactorily justified. In particular, the suggested associ-
ation between dysphagia and KIT TK II domain muta-
tions and the inability of KIT TK I domain mutations to
affect skin pigmentation [11, 16] proved wrong [13, 28,
35]. Acute myeloid leukemia, seminoma/dysgerminoma
and sinonasal NK/T-cell lymphoma, neoplasms related
to KIT mutations (often in exon 17) [49], at the best of
my knowledge have never been described in germline
KIT-mutants (curiously, some familial germ-cell tumors
revealed somatic KIT mutations [59]). K559I and D816V
KIT mutations, found in GISTs, can cause familial mas-
tocytosis without detectable GISTs [38, 60–63]. Thus,
genotype-phenotype correlation appears loose [39].
KIT mutations in sporadic GISTs cluster in exons 11,
9, 13, 17 and 8, with a frequency of ~65 %, ~8 %, ~1 %,
~1 % and < <1 %, respectively [2, 64]. In germline mu-
tants, however, the KIT mutational spectrum differs
(Table 1). In fact, focusing each single GIST oncogenic
mutation arousal (counting each KIT-mutant kindred as
one): 1) mutations involve exon 9 in 1/37 (3 %) and exon
17 in 4/37 (11 %) cases; 2) among exon-11 mutations,
substitutions (61 %) prevail over deletions and insertion/
deletions (29 %) (reversing the 31 %/60 % proportion
found in sporadic GISTs); 3) KIT exon-11 mutations ap-
pear enriched in p.V559A, p.W557R and p.L576P substi-
tutions (48 %, versus 10 % of sporadic GISTs) [58].
These differences suggest a selection of favorable geno-
types in germline mutants, possibly less life-threatening,
because: 1) exon-9 mutations proved aggressive in
imatinib-naive GISTs; 2) exon-17 mutations appear
more favorable than exon-11 ones [65]; 3) 5’-end exon-
11 mutations, especially deletions, are likely biologically
severe [30]; 4) sporadic GISTs with exon-11 substitu-
tions or duplications revealed smaller than those with
exon-11 deletions, and the former featured lower mitotic
rates, supporting a lower biological impact of exon-11
substitutions; 5) GISTs bearing p.V559A, p.W557R andp.L576P mutations tend to feature better relapse-free
survivals [58].
The first step of GIST tumoral progression in germline
KIT-mutants is ICCH. “ICCH” and “micro-GIST” are
terms applied to a variety of microscopic/tiny CD117+
cell lesions. Despite gross dimensional criteria have been
proposed for separating them [66], a distinction between
diffuse (ICCH) and nodular/focal (micro-GISTs) lesions
prevails [2, 50]. Thus defined, ICCH is a non-neoplastic
polyclonal lesion [10], constituting the only known GIST
precursor. Subsequent events leading to overt tumors
follow those found in sporadic GISTs: chromosomes 14
and 22 deletions [20], and loss of heterozigosity (LOH)
involving the KIT wild-type (WT) allele at progression
to malignancy [29]. The oncological impact of individual
syndromic KIT-mutant GISTs is estimated using the pa-
rameters adopted for their sporadic counterparts [67].
Besides, germline KIT-mutant subjects may suffer fre-
quent/severe gut occlusion/hemorrage, due to the tumor
numerousness.
KIT mutations alter KIT structure simulating SCF-
binding induced activation (if in exons 8 and 9, coding for
the extracellular, ligand-binding domain), or allowing the
kinase activation loop to switch to activation (exon 11, jux-
tamembrane regulatory domain), or directly imparting an
active conformation to TK domains (exons 13 and 17,
intracellular ATP-binding region and activation loop, re-
spectively). This explains the differences in imatinib sensi-
tivity depending on the KIT-mutant exon [50], either
germline or not. Relatively better results are achieved when
mutations occur “upstream” to the imatinib targeted site
(i.e. in KIT exons 8, 9 and 11; for the rare exon 8 mutations
evidences are limited [22, 64]), while the highest resistance
rates are found in exon-13 and 17 mutations [50].
Table 1 details the features of the published germline
KIT mutant kindreds/individuals manifesting GISTs.
PDGFRA-mutant syndrome
PDGFRA is a type III TKR whose gene is mapped to
4q12 [51], probably sharing with KIT a common ances-
tor [68]. PDGFRA is physiologically activated through
binding to all PDGFs except PDGF-DD [69], triggering
the same pathways elicited by KIT [50] (Fig. 1), albeit
differentially activating PI3K/AKT/mTOR over RAS/
MAPK [70]. Coherently, activating mutations of
PDGFRA and KIT can raise similar tumors and are usu-
ally mutually exclusive.
At the best of my knowledge, germline PDGFRA-mu-
tant GISTs have been signaled in two kindreds and in an
individual without familial history [45–48]. A PDGFRA-
mutant family bearing intestinal tumors defined as
GISTs, but lacking GIST hallmarks except PDGFRA sta-
tus, has also been reported [71]; these tumors are prob-
ably fibrous tumors, possible variants of another GI
Ricci Hereditary Cancer in Clinical Practice  (2016) 14:15 Page 7 of 15PDGFRA-driven tumor: inflammatory fibroid polyp
(IFP) [48]. Moreover, a germline PDGFRA-mutant indi-
vidual bearing multiple IFPs (and a likely PDGFRA-unre-
lated GIST hosting a somatic KIT mutation) has been
reported very recently [72]; this individual shares both
germline defect and geographical origin with one of the
above mentioned kindreds [48], and is therefore prob-
ably related to it. Finally, three families featuring mul-
tiple IFPs have been described without PDGFRA
genotyping [73–76]. PDGFRA-mutant syndrome is the
term proposed for defining this clinical spectrum [48],
formerly termed “intestinal neurofibromatosis/neuro-
fibromatosis 3b” [71, 77, 78].
First diagnoses of IFP (including tumors misdiagnosed
as neurofibromas) tend to precede those of GIST (means
40.6 and 48.1 years, respectively, p = 0.12 -Mann–Whit-
ney U Test-) in PDGFRA-mutant syndrome, suggesting
a faster IFP tumorigenesis (of note, IFP and GIST are
unrelated lesions) [45, 47, 48, 71, 72, 78].
Although PDGFRA-mutant syndrome features an
autosomal dominant pattern of inheritance with high
penetrance [48], the sex distribution of GI tumors is ap-
parently unbalanced, with a 4:11 male-to-female ratio
(7/15 considering also pathologically undiagnosed GI tu-
mors). Affected females outnumber males (11:1) also in
ungenotyped kindreds featuring familial IFPs or “intes-
tinal neurofibromatosis/NF3b” (12:2 including suspected
GI tumors) [45–48, 71–78]. However, females prevail
(14:5) also among the 19 ascertained PDGFRA-mutants,
compensating the corresponding 10:4 female-to-maleTable 2 Kindreds and individuals affected by PDGFRA-mutant syndro






















Ricci et al. [48] family 14
(p.P653L)
yes
Ricci et al. [72] Individual (mother and
grandmother suffered a gut
occlusion) (likely related







a: SI small intestine, ST stomach
b: E epithelioid, M mixed spindle cell and epithelioid; S spindle cell
c: Inflammatory fibroid polyp
d: Fibrous tumor is likely a variant of IFP [48]
e: When a germline PDGFRA mutation was found in the referred kindred, these tum
tumors known at that timetumor distribution (coherently, Fisher exact test, one-
tailed, proved not significant: p = 0.60).
PDGFRA-mutant GISTs (germline or not) are mostly
at-least-in-part epithelioid, and gastric [48, 50]. The lat-
ter location appears so far exclusive in germline-mutant
examples, as the only extra-gastric GIST reported in this
genetic setting bore a concomitant somatic KIT muta-
tion, and likely hinged exclusively on it [72]. PDGFRA-
mutant GISTs express CD117 (less frequently than KIT-
mutant GISTs and often weakly/patchy) and DOG1.
PDGFRA-mutant syndrome may also feature IFPs (in-
cluding GI fibrous tumors), GI lipomas or large hands
(Table 2). Diffuse ICCH has never been described in
germline PDGFRA mutants; the reported “focal ICCs”
[45] rather fits micro-GIST. These findings support
PDGFRA-mutant and KIT-mutant GISTs as distinct en-
tities. Accordingly, GI motility disturbance, frequently
accompanying ICCH, is not typical of PDGFRA-mutant
syndrome. Although the PDGFRA role in GIST and IFP
pathogenesis [79] justifies the presence of these two tumor
types in PDGFRA-mutant syndrome, the occurrence of GI
lipomas (sporadic GI lipomas revealed PDGFRA WT [80])
and large hands, and the variability of the observed
phenotypic assortment are presently unexplained.
GIST PDGFRA mutations cluster in exons 12 (juxta-
membrane regulatory domain), 14 and 18 (TK domains
-ATP binding region and activation loop, respectively-).
Mutations in all of these exons are represented in
PDGFRA-mutant syndrome (Table 2). Two of them (in-
volving exon 12) are relatively indolent, one atme
Associated signs






















ors were considered GISTs since GISTs were the only PDGFRA-mutant GI
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risk (exon 18-non-p.D842V) [65]. Besides, PDGFRA
exon-14 mutations proved prognostically favorable in
another work [81]. Similarly to KIT-mutant GISTs
(counting each kindred as one, and considering the re-
cently reported p.P653L individual [72] as a member of
a previously published PDGFRA-mutant family [48]
given the identity of both genetic defect and geograph-
ical origin), with the caveats of the limited sample,
PDGFRA mutation distribution differs in germline muta-
tions with respect to sporadic GISTs, with exon 18 in-
volved in 25 % (Table 2) and 82 % [65] of cases,
respectively. Germline-mutants appear enriched in pre-
sumably low-biological-impact mutations [65], with low
molecular risk exon-12 ones found in 50 % of cases.
Germline PDGFRA-mutant GISTs feature 14q LOH
[46], similar to sporadic, germline KIT-mutant and NF1-
associated ones.
In PDGFRA-mutant kindreds, small bowel occlusions
due to IFP can be life-threatening. Of note, only one in-
dividual died of malignancy possibly related to GIST de-
scribed as “gastric cancer” in the absence of pathological
records [48], coherently with the relative indolence of
PDGFRA-mutant GISTs [82]. In need of treatment, how-
ever, TKI use must be pondered, evaluating the specific
mutation present. In fact, although never reported in
germline-mutants, p.D842V, the most common PDGFRA
mutation of sporadic GISTs, confers resistance to
both imatinib and the second-line TKI sunitinib, justi-
fying alternative approaches using dasatinib and cre-
nolanib [83–85].
Table 2 details the features of published PDGFRA-mu-
tants syndrome cases.
NF1-associated GISTs
Neurofibromin, encoded by NF1 gene on 17q11.2 [51],
accelerates the conversion from active GTP-bound to in-
active GDP-bound RAS. NF1 inactivation stimulates
MAPK cascade through increasing RAS activity [50],
promoting tumorigenesis (Fig. 1).
NF1 is relatively common, with a ~1:3,000 birth inci-
dence and a 1:4–5,000 prevalence [86]. NF1 transmis-
sion is autosomal dominant with complete penetrance
and variable expression. ~50 % of NF1 lack familial his-
tory due to the high human NF1 mutation rate. In NF1,
one NF1 allele is germline-mutant, the other displays tu-
moral somatic inactivation.
National Institutes of Health NF1 diagnostic criteria
consist of ≥2 among: ≥6 café-au-lait macules >5 mm or
>15 mm in pre-pubertal or post-pubertal subjects, re-
spectively; ≥2 neurofibromas (one if plexiform); axillary/
inguinal freckles; optic glioma; ≥2 iris hamartomas; bony
dysplasia; and a NF1-affected first-degree relative [87].
0.1-6 % of NF1 feature paragangliomas [88].Clues of a possible association between NF1 and GIST
have been known for decades [89]. As differential diag-
nosis between neurofibroma (NF) and GIST was made
reliable [90], this association became evident. GISTs are
the most frequent GI NF1 manifestation with a 7 %
prevalence in NF1 patients, increasing to 25 % at aut-
opsy. NF1 is >45-fold overrepresented among GIST pa-
tients. Coherently, NF1-mutated GISTs account for
~1,5 % of all GISTs. Average age-at-diagnosis of NF1-
associated GISTs is ~49 years [1, 86, 91, 92].
NF1-associated GISTs are often multiple and small in-
testinal, with possible gastric exceptions (NF1 frequency
is 6 %, 4 % and 0.06 % among patients with duodenal, je-
junal/ileal and gastric GISTs, respectively); singly consid-
ered, they do not differ from sporadic intestinal GISTs,
mostly featuring spindle cells, collagen globules (skei-
noid fibers) and CD117 positivity [91]. Other NF1 GI le-
sions include: ICCH, with related GI motility disorders,
and neuroendocrine tumors (especially periampullary
somatostatinomas) [86]. The awareness of these GI signs
can help to avoid diagnostic omissions caused by the
variable clinical presentation and frequent non-familial
form of NF1 (the lack of NF1 mutational hotspots makes
genotyping an unpractical diagnostic tool) [86].
The discovery of NF1 second-hit in NF1 GISTs,
already revealed peculiar because of their usually WT
KIT/PDGFRA [91, 93], disclosed their pathogenesis and
molecular link with NF1 [94]. KIT/PDGFRA mutations
in NF1-associated GISTs are nevertheless possible, al-
though probably incidental [95], globally accounting for
~8 % of cases [96].
NF1 GIST tumoral progression resembles that of
germline KIT mutants, featuring preneoplastic ICCH
followed by 14q and 22q LOH [97].
Although mostly indolent, ≤15-20 % of NF1 GISTs be-
have aggressively [91, 93]. NF1 GISTs are poorly respon-
sive to imatinib, since NF1 trigger occurs downstream to
imatinib targets KIT/PDGFRA; coherently, NF1 GISTs
should not be treated with adjuvant imatinib, whatever
their risk [98–100].
Syndromic SDH-deficient GISTs
SDH is a 4-subunit (A/B/C/D) Krebs cycle enzymatic
complex, located in the inner mitochondrial membrane,
but encoded by chromosomal DNA. SDHA/B/C/D (col-
lectively, SDHx) are mapped to 5p15.33, 1p36.13, 1q23.3
and 11q23.1, respectively [51]. Whatever subunit is dam-
aged, the entire complex is hampered, impairing
succinate-to-fumarate conversion; succinate accumula-
tion inhibits prolyl-hydroxylase, decreasing the hydroxyl-
ation of hypoxia-inducible factor (HIF)-1α (HIF-1α)
and its consequent degradation; HIF heterodimers can
thus translocate into the nucleus initiating tumori-
genic transcription. Furthermore, succinate accumulation
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methylcytosine conversion to 5-hydroxymethylcytosine,
required for DNA demethylation; coherently, SDHx-defi-
cient GISTs feature pervasive DNA hypermethylation,
likely implied in oncogenesis [101–105] (Fig. 1).
SDH-deficiency characterizes the largest KIT/PDGFRA-
WT GIST subgroup (accounting for ~5 % of GISTs) [1].
SDH deficiency is also a feature of paragangliomas, renal
cell carcinomas and pituitary adenomas [106, 107]. SDH-
deficient GISTs arise either in germline SDHx-mutant
and/or manifest syndromic settings or not [105, 108].
Thus, not surprisingly, in case of constitutive predis-
position to SHD-deficiency, GISTs can associate with
paragangliomas producing two syndromes: Carney’s
triad (CT) and Carney-Stratakis Syndrome (CSS), both
affecting young people (mean ages-at-diagnosis 22
and 19 years −22 and 24 years concerning GIST
only-, respectively) [109–111]. CT and CSS are sepa-
rated by the presence of pulmonary chondromas and of a
striking female predilection in the former, and of an
autosomal-dominant inheritance pattern in the latter, with
incomplete penetrance [111]. Additionally, CT may fea-
ture esophageal leiomyoma and adrenal cortical adenoma
[110]. SDH-deficient GISTs are restricted to stomach
(especially antrum) and show a multinodular pattern
(referred to as “plexiform” by pathologists) [103, 110].
≤50 % and ≤10 % of SDH-deficient GISTs manifest
lymph-vascular invasion and lymph node metastases, re-
spectively [112], explaining the frequent relapses despite
apparently radical surgery.
SDH-deficient GIST are mostly at-least-in-part epithe-
lioid, and express DOG1, CD34 (≥75 % of cases) and
CD117 (strongly/diffusely, unlike PDGFRA-driven
GISTs) [103, 110]. They are peculiarly SDHB-, whatever
the damaged SDH subunit (unlike SDHA positivity, lost
only in SDHA-mutations), and overexpress insulin-like
growth factor 1 receptor (IGF1R) [103, 113–115].
Only micro GISTs have been found to precede overt
SDH-deficient syndromic GIST [116]. ICCH is not a fea-
ture of CT [110], nor has ever been described in SDH
deficiencies.
The basis of SDH impairment in CSS is mutational,
with a typical second-hit mechanism involving SDHB/C/
D [117, 118]. Significantly, germline SDHA mutations,
described in patients bearing GISTs or paragangliomas
and in paraganglioma/pituitary adenoma familial associ-
ations, are unreported in CSS, possibly due to their low
penetrance [106, 108, 115, 118–125]. Of note, at the best
of my knowledge, the only SDHD-mutant CSS with a re-
ported pedigree hinged on a paternally inherited defect-
ive allele [126], coherently with the parent-of-origin
effect of SDHD-depending hereditary paraganglioma
syndrome PGL1, simulating maternal imprinting. How-
ever, SDHD lacks physical imprinting and PGL1 isexceptionally maternally transmitted, invoking the in-
volvement of a second, paternally imprinted, tumor sup-
pressor gene (TSG) (possibly H19) located on 11p15, i.e.
the same chromosome of SDHD. Both WT SDHD and
functional 11p15 TSG can thus be inactivated by non-
disjunctional loss of the maternal chromosome 11, justi-
fying the paternal disease transmission. More complex
events, such as mitotic recombination of 11p15 TSG
followed by loss of the paternal chromosome, would ex-
plain the exceptional maternal transmission [127–129].
Unlike CSS, CT tumorigenesis depends on epigenetic
tumoral SDHC inactivation through SDHC hypermethy-
lation [130]. This phenomenon, distinct from the global
DNA hypermethylation of SDH-deficient GISTs as a
whole, is common to most SDH-deficient, SDHx-WT
GISTs, irrespective of CT presence; however, “non-CT”
cases could be formes frustes of CT, as suggested by the
mosaic constitutional SDHC promoter hypermethyla-
tion, implying a risk for metachronous paraganglioma/
pulmonary chondroma [105].
Another oncogenic stimulus of SDH deficient GISTs
is the hyperactivation of the IGF1R pathway, physio-
logically involved in cell survival/proliferation [113,
131].
≥50 % CT GISTs do not bear chromosomal imbal-
ances; their rare LOHs preferentially involve 1p; 14q or
22q losses occur infrequently [132].
SDH-deficient GISTs often behave indolently, even in
case of metastases, probably due to the metabolic disad-
vantage caused by SDH deficiency. They can neverthe-
less be aggressive (the SDH-deficient GIST overall
mortality approaches 15 %). Of note, current risk classi-
fications do not fit SDH-deficient GISTs [110, 112].
TKI imatinib and sunitinib proved ineffective or only
partially effective, respectively, in SDH-deficient GISTs,
coherently with SHD deficiency constituting a pathway
independent of KIT/PDGFRA. Therefore, in the absence
of guidelines specific for these tumors, TKI treatment is
suggested for progressive disease but not after complete
surgical resection [98–100, 112]. Inhibitors of IGF1R are
being evaluated: testing of linsitinib in adult and
pediatric WT GISTs (enriched in SDH-deficient GISTs),
although without evidence of RECIST response, indi-
cates a 45 % clinical benefit/52 % progression-free sur-
vival at 9 months [133]. When compared to KIT-mutant
GISTs, a higher fraction of KIT/PDGFRA-WT (and
PDGFRA-mutant) GISTs displayed activation of the
mTOR pathway [70]; Therefore, CT/CSS GISTs can po-
tentially benefit of PI3K/AKT/mTOR inhibitors [131].
Regorafenib, nilotinib, sorafenib and heat-shock protein
inhibitors are other drugs potentially usable; finally, tar-
geting of HIF-1α, α-ketoglutarate, and demethylating
agents such as decitabine are theoretically attractive ap-
proaches [104, 105, 134–136].
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on the presence or not of pulmonary chondromas,
germline SDHB/C/D mutations and inheritance; female
predilection of CT is another helping feature [137].
However, the arousal of tumors in SDH-deficient syn-
dromes, including CT and CSS, can span over dozens of
years [112]. Thus, if the “missing” tumor of a CT is pul-
monary chondroma, CT/CSS morphologic differential
diagnosis is impossible. Under these circumstances, in
the absence of familial history, genotyping becomes piv-
otal. But recent findings have eroded also this corner-
stone, evidencing germline SDHA/B/C variants, at least
part of which pathogenic, in 6/63 (9.5 %) CT patients
“certified” by pulmonary chondromas. On top of that,
unlike typical CT, these patients were equally distributed
between sexes [138]. Additionally, three males diagnosed
with CT (one with a lesion “consistent with pulmonary
chondroma”) were subsequently found to bear germline
SDHx mutations [105, 139]. Noticeably, CT diagnosis in
these cases appears questionable, with genotype and sex
distribution rather supporting CSS.
GISTs could be also considered an infrequent compo-
nent of SDH-deficient paraganglioma syndromes PGL1/
3/4/5 [140], depending on SDHD/C/B/A germline muta-
tions, respectively [141]. A risk of WT SDHx allele loss
lower in GIST precursor cells than in paraganglial ones
could explain the relative GIST rarity [112]. Noticeably,
associations between GIST and renal cell carcinoma, an-
other SDH-deficient tumor reported in paraganglioma
syndromes, has been found in germline SDHA/B/C mu-
tants [141–144].
Perhaps CT, CSS and PGL1-5 will be reconsidered in
the future as different aspects of a single SDH-deficient
disease.
Practical approach to GIST-predisposing syndromes
GIST-prone syndromes must be suspected in the pres-
ence of GISTs either multiple or associated with the pe-
culiar manifestations previously described (which can
raise suspicions even by themselves) (Table 3). Genotyp-
ing, if applicable, is confirmatory. NCCN guidelines sug-
gest to investigate every KIT/PDGFRA-WT GIST
patient for germline SDHx mutations [84]. Multiple
GISTs sharing a phenotype not found in the germline
favor a metastatic condition.
Comprehensive guidelines specific for the manage-
ment of GIST-prone syndromes are lacking. Existing
recommendations, dealing with adjuvant therapy of
NF1-associated and SDH-deficient GISTs [99], have
been treated in the pertaining chapters of this review.
Once a patient is diagnosed with a GIST-predisposing
condition depending on a germline DNA defect, predict-
ive genetic testing in family members should be consid-
ered. The latter is indicated for the highly penetrantgermline KIT/PDGFRA/SDHB/SDHD mutations; con-
versely, the opportunity of genetic evaluation is contro-
versial for the low penetrance SDHC and, especially,
SDHA variants [141]. It is worth recalling the parent-of-
origin effect of familial SDHD mutations, herein previ-
ously discussed.
Periodic computed-tomography-scan or 18F-FDG PET-
computed-tomography have been suggested for the sur-
veillance of syndromic GISTs [145]. Endoscopic ultra-
sound joined to fine needle tissue acquisition allowing
histological assessment [146, 147] appear valid comple-
ments. Colonscopy is expectedly of limited utility in fa-
milial KIT-dependent GISTs [29] (mostly gastric/small
intestinal) and useless in SDH-deficient ones (strictly
stomach restricted), while can detect colonic/ileal IFPs
in PDGFRA-mutant syndrome [48]. In case of SDH-
deficient GISTs, chest X-ray is indicated to look for pul-
monary chondromas (especially if SDHx-WT), and
plasma/urine determination of metanephrines/catechol-
amines and PET-tracers 68Ga-DOTATATE, 18F-DOPA
and 18F-FDA can be used for investigating paraganglio-
mas [141].
Intracellular signaling machineries and gene expres-
sions are common to homologous syndromic and spor-
adic GISTs [20]. Coherently, no differences in imatinib
sensitivity exist between GISTs sharing the same geno-
type, no matters whether somatic or germline [98].
Thus, the approach to individual syndromic GISTs in
need of treatment does not differ from that to their
sporadic counterparts.
There is no evidence that GIST hereditary predisposi-
tions constitute an independent prognostic factor warrant-
ing a differential GIST treatment [145]. Nevertheless, the
frequent multiplicity of GI tumors constitutes a problem
peculiar to GIST-syndromes deserving a special attention,
commonly causing acute complications such as hemor-
rage and, especially in germline KIT/PDGFRA mutations
and NF1 (where the small bowel can be involved), occlu-
sion/perforation which can be life-threatening [13, 43, 48].
Although surgery is frequently necessary as affected pa-
tients are often symptomatic [13], no agreement exists as
to whether preventive therapy, either surgical or molecu-
larly targeted, is indicated in asymptomatic subjects [145].
It has been suggested to postpone surgery based on the
frequent indolence of germline-mutant GISTs [148]; how-
ever, the latter’s possible aggressiveness recommends to
remove GISTs at presumable significant risk, based on
size/site/genotype. Similarly, lesions at risk of occlusion/
hemorrhage should be removed too. Surgery should focus
on resecting the outstanding tumor(s) disregarding pos-
sible tiny nodules if numerous and involving extended
areas, since their removal would sacrifice substantial por-
tions of functional GI tissue without proven benefit in
terms of tumor recurrence risk; this is particularly true in
Table 3 Main features of GIST-predisposing syndromes
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[109]. Preventive molecular therapy poses several prob-
lems. In fact, although theoretically attractive, it is pres-
ently not evidence-based. Prospective clinical trials will be
hardly achieved, given the rarity of syndromic GISTs.
Moreover, the risks of lifelong exposures to GIST-targeted
drugs are presently unknown. Thus, active surveillance
has been adopted after surgery [44]. Alternatively, a long
term preventive treatment with TKI in patients bearing a
sensitive mutation has been proposed [13]. A compromise
has been adopted by employing half-dose imatinib in a
KIT exon-11 germline mutant with multiple GISTs,
obtaining marked tumor reductions after one-year [43].
Interestingly, imatinib therapy has been reported to
reduce cutaneous melanosis in germline KIT-mutants [32,
41].
Exceptionally, GISTs in syndromic contexts can reveal
superimposed triggers [96, 149]. Anomalous GIST site
and/or morphology with respect to a given hosting syn-
drome can help in suspecting these “divergent” GISTs,
whose pathogenesis can hinge mainly or even exclusively
upon the “extra-syndromic” molecular defect, with rele-
vant clinical implications [72]. In any event, to be on the
safe side it is advisable to fully genotype whatever appar-
ently syndromic GIST to be molecularly treated, inde-
pendently of its morphology and site.Conclusions
The correct approach to syndromic GISTs results from
the integration between congruent diagnostic strategies,
including familial screening, and treatment of individual
tumors and background syndromic manifestations. Pro-
tean signs prompt to undertake complex choices involv-
ing the treatment of symptomatic lesions and the
prevention of future complications. Specific comprehen-
sive guidelines are lacking, primarily due to the rarity of
syndromic GISTs. However, these diseases have been the
subject of an increasing number of publications, result-
ing in a conspicuous amount of data with relevant clin-
ical implications. The latter allowed the draft of the
present review, which hopefully will help physicians fa-
cing GIST-prone syndromes, waiting for the develop-
ment of dedicated guidelines.Abbreviations
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